Molecular diagnostic labs are increasingly turning to CGP and bringing the power of precision oncology directly into the hospital. However, implementing CGP testing in-house presents several onboarding and verification barriers. In this case study, learn how a leading academic medical center adopted the FDA-cleared PGDx elio™ tissue complete solution with faster time to market while reducing implementation burdens, increasing operational efficiency and simplifying the path to reimbursement.
Case Study
Download our case study to learn how Labcorp’s PGDx elio™ tissue complete is making CGP more accessible for routine cancer care.